Clin2
NCT06372821Likely a fitRecruiting

Study of NIO752 for Alzheimer's disease

Alzheimer DiseaseAutosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Part of Brain & nervous system, Mental health clinical trials.

This study tests an experimental drug called NIO752 to see if it can reduce the production of tau protein, which is linked to Alzheimer's disease. Researchers will measure how the drug affects tau in your body using a special technique called SILK.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
10 people
Ages
21 years to 80 years
Study type
Interventional

Who can take part

  • You are between 21 and 80 years old.
  • You have mild or moderate Alzheimer's disease, confirmed by a doctor and backed up by a test (like spinal fluid, PET scan, or blood test).
  • You are fluent in English and have a caregiver who can help you.
  • You can have spinal taps (lumbar punctures), MRI scans, and blood draws.
  • You agree to share your data and samples with the study's commercial partner (Novartis).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07058688Recruiting· Phase 2
Testing a new drug for Alzheimer's (NTRX-07)

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Brno
NCT07598370Recruiting· Phase 1
Testing LY3439539 for early-stage Alzheimer's disease

This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.

Irvine, California
NCT06761066Enrolling by invitation
Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's

This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.

Seoul
NCT07236190Recruiting· Phase 2
Testing NPC-1 for people with Alzheimer's signs

This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.

Boston, Massachusetts
NCT06885567Not yet recruiting· Phase 2
Testing a new drug for early Alzheimer's disease

This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.

Seoul
NCT06995573Recruiting· Phase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness

This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.

Salzburg, State of Salzburg

Hear when a new Alzheimer Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.